Author

D. Trastulli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Andrade· 1 shared A. Di Martino· 1 shared A. Gomez· 1 shared A. Oaknin· 1 shared A. Vidal· 1 shared A. Villanueva· 1 shared A. Villarrubi· 1 shared B. Duso· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Andrade

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Inhibiting LSD1 suppresses coronavirus-induced inflammation but spares innate antiviral activity

L. Mazzarella, F. Santoro, R. Ravasio, P. Massa, S. Rodighiero, E. Gaviln, M. Romanenghi, B. Duso, E. Bonetti, R. Pallavi, D. Trastulli, I. Pallavicini, C. Gentile, T. Leonardi, G. Buttinelli, , P. G. Pelicci

The paper shows inhibiting LSD1 reduces coronavirus-induced inflammation while preserving innate antiviral activity in macrophages.

bioRxiv · May 2, 2021 · PreprintImmunology

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

O. A. Romero, A. Villarrubi, J. J. Alburquerque-Bejar, A. Gomez, A. Andrade, D. Trastulli, E. Pros, S. Verdura, L. Farre, J. F. Martin-Tejera, P. Llabata, A. Oaknin, M. Saigi, J. M. Piulats, X. Matias-Guiu, , M. Sanchez-Cespedes

This study identifies KDM6A/UTX and KDM6B/JMJD3 as therapeutic targets in SMARCA4-deficient cancers, showing that their inhibition reduces tumor viability in mouse models.

bioRxiv · Aug 7, 2020Cancer Biology